BRIEF-Galmed To Expand Drug Development Activities To Cancer, Cardiometabolic Diseases

Reuters09-19

Sept 19 (Reuters) - Galmed Pharmaceuticals Ltd :

* GALMED ANNOUNCES AN EXPANSION OF ITS ACTIVITIES TO CANCER AND MAJOR CARDIOMETABOLIC DISEASES

* GALMED PHARMACEUTICALS LTD - TO DEVELOP ARAMCHOL-BASED DRUG COMBINATIONS FOR CANCER

* GALMED PHARMACEUTICALS LTD - TO DEVELOP ARAMCHOL-BASED DRUG FOR CARDIAC FIBROSIS

* GALMED PHARMACEUTICALS LTD - TO RELEASE NEW DATA FROM STUDIES IN Q4 2024

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468520798?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-19 19:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468520798","market":"us","top_or_hot":-1,"title":"BRIEF-Galmed To Expand Drug Development Activities To Cancer, Cardiometabolic Diseases","media":"Reuters","content":"<html><body><p>Sept 19 (Reuters) - Galmed Pharmaceuticals Ltd   :</p><p>   * GALMED ANNOUNCES AN EXPANSION OF ITS ACTIVITIES TO CANCER AND MAJOR CARDIOMETABOLIC DISEASES</p><p>   * GALMED PHARMACEUTICALS LTD - TO DEVELOP ARAMCHOL-BASED DRUG COMBINATIONS FOR CANCER</p><p>   * GALMED PHARMACEUTICALS LTD - TO DEVELOP ARAMCHOL-BASED DRUG FOR CARDIAC FIBROSIS</p><p>   * GALMED PHARMACEUTICALS LTD - TO RELEASE NEW DATA FROM STUDIES IN Q4 2024</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Galmed To Expand Drug Development Activities To Cancer, Cardiometabolic Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Galmed To Expand Drug Development Activities To Cancer, Cardiometabolic Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-19 19:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 19 (Reuters) - Galmed Pharmaceuticals Ltd   :   * GALMED ANNOUNCES AN EXPANSION OF ITS ACTIVITIES TO CANCER AND MAJOR CARDIOMETABOLIC DISEASES   * GALMED PHARMACEUTICALS LTD - TO DEVELOP ARAMCHOL...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLMD","symbol_name":"Galmed Pharmaceuticals Ltd.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2468520798","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468520798","pubTimestamp":1726745266,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 19  - Galmed Pharmaceuticals Ltd   :   * GALMED ANNOUNCES AN EXPANSION OF ITS ACTIVITIES TO CANCER AND MAJOR CARDIOMETABOLIC DISEASES   * GALMED PHARMACEUTICALS LTD - TO DEVELOP ARAMCHOL-BASED DRUG COMBINATIONS FOR CANCER   * GALMED PHARMACEUTICALS LTD - TO DEVELOP ARAMCHOL-BASED DRUG FOR CARDIAC FIBROSIS   * GALMED PHARMACEUTICALS LTD - TO RELEASE NEW DATA FROM STUDIES IN Q4 2024Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLMD":"Galmed Pharmaceuticals Ltd.","BK4139":"生物科技"},"translate_title":"简介-Galmed将药物开发活动扩展到癌症、心脏代谢疾病","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLMD":1},"content_text":"Sept 19 (Reuters) - Galmed Pharmaceuticals Ltd   :   * GALMED ANNOUNCES AN EXPANSION OF ITS ACTIVITIES TO CANCER AND MAJOR CARDIOMETABOLIC DISEASES   * GALMED PHARMACEUTICALS LTD - TO DEVELOP ARAMCHOL-BASED DRUG COMBINATIONS FOR CANCER   * GALMED PHARMACEUTICALS LTD - TO DEVELOP ARAMCHOL-BASED DRUG FOR CARDIAC FIBROSIS   * GALMED PHARMACEUTICALS LTD - TO RELEASE NEW DATA FROM STUDIES IN Q4 2024Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468520798"}